Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Breast Cancer Invasive Nos × Breast × Clear all

Phase

Status

Sponsor Class

OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 241 Breast Neoplasms, Male 20 Breast Carcinoma In Situ 13 Carcinoma, Non-Small-Cell Lung 12 Carcinoma, Intraductal, Noninfiltrating 11 Prostatic Neoplasms 10 Neoplasm Metastasis 10 Lung Neoplasms 10 Carcinoma, Ductal, Breast 10 Colonic Neoplasms 9 Pain 8 Neoplasms 8 Colorectal Neoplasms 8 Inflammatory Breast Neoplasms 7 Carcinoma, Ovarian Epithelial 7 Ovarian Neoplasms 6 Osteoporosis 6 Fatigue 6 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Rectal Neoplasms 5 Testicular Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Sezary Syndrome 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Mycosis Fungoides 4 Multiple Myeloma 4 Melanoma 4 Lymphoma, T-Cell, Cutaneous 4

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡